Introduction
============

Recent studies have implicated glutamate (Glu) signaling in the development and progression of malignant diseases. Glu, a non-essential amino acid, is the major excitatory neurotransmitter in the central and peripheral nervous systems (CNS, PNS). In addition, it functions as a source of energy for rapidly dividing cells such as lymphocytes and cancer cells (reviewed in [@B1]). Many decades of research have demonstrated the importance of glutamatergic signaling in the CNS [@B2], [@B3]. Processes such as synaptic plasticity and learning and memory which rely on long-term potentiation are known to require functional Glu receptors [@B4].

Glu initiates signaling cascades upon binding to both ionotropic (iGluR) and metabotropic Glu receptors (mGluR) (reviewed in [@B2], [@B3], [@B5], [@B6]). The two receptor families differ in their mechanisms of activation and downstream effectors: iGluRs are voltage-gated ion channels that initiate Ca^2+^ and/or K^+^ influx and downstream signaling while mGluRs are atypical G-protein-coupled receptors (GPCRs) which activate second messenger pathways such as phospholipase C (PLC), phosphoinositide 3 kinase/retrovirus AK thymoma/mTOR (PI3K/AKT/mTOR) and mitogen activated protein kinase (MAPK) signaling (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"} & [2](#F2){ref-type="fig"}). Both receptor families are further classified into subgroups based on amino acid sequence homology, pharmacology and other signaling characteristics. First, the iGluRs are segregated into three subfamilies based on agonist binding: the N-methyl-D-aspartate (NMDAR), a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPAR), and kainate receptor (KR) subfamilies Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). Second, the mGluR family contains three subfamilies known as groups I, II and III (Table [1](#T1){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). The mGluR subfamilies differ in the second messenger systems that are activated upon ligand binding. Group I contains mGluR1 and 5 and initiates signaling via the PLC/Inositol 1,4,5-triphosphate/diacylglycerol (PLC/IP3/DAG) pathway (Figure [2](#F2){ref-type="fig"}). Group II (mGluR 2 and 3) and III (mGluR4, 6, 7, 8) activates the inhibitory G-protein, G~i~, resulting in decreased cAMP levels (Table [1](#T1){ref-type="table"}). Studies have shown that these are not rigid rules: some mGluRs are known to bind to other excitatory or inhibitory G-proteins (see [@B2] for review).

The eight mGluR genes are alternatively spliced to encode 12 isoforms (reviewed in [@B2]). As is the case for all GPCRs, all mGluR isoforms contain the typical seven transmembrane domains (TMD) as well as an amino-terminal (N-terminal) ligand-binding domain (ATD) and a carboxy-terminal (C-terminal) cytoplasmic domain (CTD) (Figure [2](#F2){ref-type="fig"}) [@B7]. The mGluRs are referred to as atypical GPCRs for a number of reasons. First, the ATD is far larger than other GPCR family members at approximately 55 kDa [@B8]. The unique two-lobed shape of this domain in which Glu binds between the two lobes is referred to as the "venus fly trap" domain [@B9]. Second, the receptors differ from classic GPCRs and further the isoforms differ from one another at the level of the CTD. The mGluR1a and mGluR5a isoforms contain a long proline-rich CTD which has been shown to participate in multiple protein-protein interactions. Downstream of the proline-rich region is the Homer1 binding motif. This domain facilitates the interaction of the active receptor with Homer1a, b and c; an event which mediates the coupling of mGluR1a/5a to multiple critical downstream signaling components [@B10]-[@B14]. Finally, the mGluR family differs from other GPCRs in that it exists as a functional homodimer. Disulfide bridging between the two receptor monomers occurs in the short cysteine rich domain (CRD) between the ATD and the TMD which contains a number of cysteine residues (Figure [2](#F2){ref-type="fig"}) [@B7], [@B15]-[@B17].

The protein-protein interactions that occur at the Homer1 binding motif of mGluR1a/5a can modulate the activity of the receptor in multiple critical ways. Characterized by the consensus sequence PPxxFR (where x is any amino acid), the Homer1 binding motif is known to recruit Homer1 proteins via the Homer Ena/VASP Homology 1 domain (EVH1) located at the N-terminus of all Homer1 isoforms [@B18]-[@B20]. The *Homer1* gene encodes multiple isoforms of varying length; the best studied of which are Homer1a, b and c \[reviewed in 21\]. Homer1b and c (known as "long form" isoforms) also contain coiled-coil and leucine zipper domains which facilite homodimerization, allowing long form Homer1 isoforms to couple the active receptor to other Homer1-bound downstream signaling components, such as Insitol triphosphate receptor (IP3R), PI3K and ERK1/2 [@B19], [@B21], [@B22]-[@B26]. In many cases, Shank scaffolding proteins are involved in these protein-protein interactions which, in neural cells, are referred to as postsynaptic densities and are critical for proper neurotransmission [@B19], [@B27]-[@B28]. In contrast to the function of other isoforms, Homer1a is shorter in length and lacks the coiled-coil domains allowing for scaffolding activity, lending to it\'s classification as a dominant-negative isoform \[reviewed in 21; 29-30\] . Since it retains the EVH1 domain, but lacks coiled-coil and leuzine zippers, Homer1a simply occupies the Homer1 binding domain without coupling to other proteins. The dynamics of Homer1a and long form isoform expression in neural cells is one mechanism of generating synpatic plasticity and modulating the interaction of mGluR1a/5a with signaling components \[see 24, 31 for example\]. Finally, Homer1 isoform binding to mGluR1a/5a can influence its trafficking between the cytoplasm and plasma membrane compartments - a fact which influences the stability of the protien [@B24].

In recent years, experimental data have implicated both iGluRs and mGluRs in malignant disease. Furthermore, many studies have indicated that mGluRs are the predominant mediators of glutamatergic signaling in cancer. Importantly, mGluR1 was recently found to be overexpressed in human prostate tumors and further, serum Glu levels correlated with primary prostate cancer (PCa) aggressiveness [@B31], [@B32]. In addition, rodent mGluR1 protein expression has been shown to cause phenotypes associated with cellular transformation in cultured melanocytes [@B33], [@B34]. These data indicate that mGluR1 can function as an oncogene in certain cell types and that Glu and mGluR1 may be important markers of disease progression in some cancers. In this review, we discuss the current state of Glu signaling research in cellular transformation and in the translational application of these studies to preclinical studies and clinical trials. We focus on the best-studied cancers in which Glu signaling has been implicated: glioma, melanoma and breast and prostate carcinoma. We conclude that there may be similarities between these cancers with respect to glutamatergic signaling and that mGluR1 is an important new target in anti-cancer drug discovery.

Glutamate blockade for the treatment of benign neurological and psychiatric disorders
=====================================================================================

Aberrant Glu signaling is implicated in the etiology and progression of many neurological and psychiatric disorders such as neurodegenerative disease (NDD), severe autism, Fragile X syndrome (mental retardation), schizophrenia, long-term depression, bipolar disorder and recovery after traumatic CNS injury (for reviews, see [@B6], [@B35]-[@B43]). In some cases (i.e. schizophrenia), a lack of mGluR signaling is thought to be a contributor to disease severity and mGluR agonists have been successful in providing some symptomatic relief [@B44], [@B45]. However, this research is plagued by the high side effects associated with mGluR agonists (reviewed in [@B46]). Current efforts are focused on developing a molecule with better tolerance and a higher penetrance for symptomatic relief in schizophrenia patients [@B46]. In many other cases, overstimulation of GluRs by excessive Glu release or persistence of Glu in the synaptic cleft is correlated with disease onset or symptomatic severity - a phenomenon called excitotoxicity [@B47]. In this situation, the excitatory amino acid transporter (EAAT) system which is usually responsible for removing Glu from the synaptic cleft after signal transduction is either unable to keep up with the flood of excess Glu, or is rendered nonfunctional. Therefore, blockade of Glu release, receptor antagonism or inhibition of downstream signaling has been used extensively in the treatment of NDDs, psychiatric maladies and to protect against permanent neural damage post-injury [@B48].

Many Glu signaling antagonists have been described in the literature and have had success in the clinic as treatments for neurological disorders [@B2], [@B3], [@B49]-[@B54]. Research into GluR antagonists as treatments for major depressive disorder (MDD) have shown that iGluR signaling blockade can be highly successful (reviewed in [@B55]). Ketamine, a noncompetitive NMDAR antagonist, provides symptomatic relief in MDD patients within hours of infusion [@B56], [@B57]. This finding was especially significant because patients that were resistant to antidepressants still responded well to ketamine, therefore opening the possibility that Glu signaling blockade may be a viable treatment option for other drug-resistant mood disorders such as lithium-resistant bipolar disorder [@B58]. mGluRs may also be targets for therapeutic intervention in patients with mood disorders. Indeed, the mGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine (MPEP) and 3-\[(2-methyl-1,3-thiazol-4-yl)ethynyl\] pyridine (MTEP) have been shown to decrease depression-related behaviors in rats [@B58], [@B59]. A new mGluR5 antagonist with potential activity against MDD and other mood disorders, BCI-838, is currently being tested for safety in the clinic (Clinicaltrials.gov \#NCT01548703).

Perhaps one of the most successful uses of Glu-targeted therapeutics is represented by the treatment of the NDD amyotrophic lateral sclerosis (ALS) with the drug riluzole [@B60]. Marketed by Sanofi-Aventis as Rilutek, FDA-approval for this drug as a treatment for ALS was achieved in 1995 [@B61], [@B62]. Since then, it has been suggested as a therapy for bipolar or major depressive disorders, but has not been granted FDA-approval for these indications [@B63]. In fact, Clinicaltrials.gov reveals that this drug is under investigation in the clinic for a number of other neurological disorders such as obsessive-compulsive disorder (Clinicaltrials.gov \#NCT00523718), MDD (\#NCT01204918), multiple sclerosis (\#NCT00501943), autism (\#NCT01661855), Huntington\'s disease (\#NCT00277602), Parkinson\'s disease (\#NCT00013624), Cervical spondylotic myelopathy (\#NCT01257828), neural protection after traumatic spinal cord injury (\#NCT01597518), as well as in various combination therapies and as treatment for other psychiatric disorders.

Classified as an "anti-excitotoxic" drug, riluzole blocks the release of Glu from the cell and may also block the activity of mGluR1a [@B64]. Although riluzole appears to antagonize NMDA and kainate receptors from electrophysiology data (reviewed in [@B65]), *in vitro* studies have been unsuccessful in demonstrating direct binding of the molecule to these receptors. In fact, it is still not completely clear exactly which Glu receptors are affected by riluzole [@B64]-[@B67]. As will be discussed in future sections of this review, riluzole shows promise as an anti-cancer therapeutic [@B67]. The drug is well-tolerated at high doses in long-term treatment paradigms with low side effects, making it an ideal medicine.

Glutamate signaling in malignant diseases
=========================================

Throughout the decades, members of the GluR family have been studied for their potential role in cellular transformation, in cancer progression, and as diagnostic and therapeutic targets. Indeed, expression of at least one subunit of iGluR or mGluR has been reported in carcinoma of the breast, prostate, thyroid and lung as well as in oral squamous cell carcinoma, colorectal cancer, melanoma, osteosarcoma, neuroblastoma, astrocytoma, multiple myeloma, glioma, medulloblastoma and some leukemias [@B34], [@B68]-[@B70]. This list is likely not all-inclusive since studies implicating Glu signaling in malignant disease are rapidly being published. This literature is confounded by a general lack of studies on the human orthologues of Glu receptors and further by the fact that in most studies, only one subunit of a particular GluR is examined.

In addition to expression differences in iGluRs in benign versus malignant cells, somatic mutations in iGluR genes have been described. First, one report proposes that iGluRs are upregulated in an androgen-stimulated manner in the PCa cell lines LNCaP and PC-3 [@B71]. Second, current work by Endele, *et al*. has identified somatic mutations in the NMDAR family members Glu receptor subunit zeta-2A and -2B (GRIN2A and GRIN2B) that impart susceptibility to not only schizophrenia but also to melanoma [@B72]. The mechanism for the involvement of iGluR signaling in melanoma seems to be related to the receptor\'s inability to allow Ca^2+^ influx and the downstream signaling repercussions [@B72]. Further, Wei, *et al*. recently catalogued somatic mutations in the iGluR superfamily in melanoma patients where they are found with high mutation frequency [@B73]. Interestingly, the expression of iGluRs may be regulated by DNA methylation since at least one study reported that not only is the promoter of Glu receptor ionotropic kainate 2 (GRIK2) differentially methylated depending on the tissue type analyzed but also that the gene is silenced by hypermethylation in gastric cancer cell lines [@B74]. Moreover, GRIK2 may have tumor suppressor activity in normal gastric epithelium since expression of the gene in normal cells results in decreased colony formation and invasion [@B74]. These data indicate that there may be a role for iGluR signaling in the development and progression of some cancers. Follow up studies will be needed to determine whether these effects are due to Glu binding directly to iGluRs or whether these effects are mediated by coupling to mGluRs**.**

In addition to the mutations uncovered in iGluR genes, somatic mutations in the mGluRs (e.g., mGluR1, mGluR3, mGluR5) have also been reported to promote breast cancer, melanoma and renal cell carcinoma growth and progression *in vivo* [@B75]-[@B80]. Using high throughput studies in cancer genomics, a relatively high number of missense and nonsense mutations were identified in human *mGluR1a* in a wide variety of cancers such as: adenocarcinoma and squamous cell carcinoma of lung, triple-negative breast cancer, basal cell and ductal carcinoma of the breast, adenocarcinoma of the large intestine, lymphoma and leukemia, high-grade astrocytoma, squamous cell carcinoma of skin and upper aerodisgestive tract, and serous carcinoma of ovary [@B81]-[@B83]. This work has led to the discovery of multiple mutations in the ligand binding domain (LBD), TMD and CTD in *mGluR1a* (Table [2](#T2){ref-type="table"}) [@B81]-[@B88]. Interestingly, most of the base changes reported thus far have been missense mutations which may suggest that truncation of the protein is not favorable for cellular transformation. Moreover, all of the mutations discussed in Table [2](#T2){ref-type="table"} have been uncovered in various types of cancer. Future studies that determine the penetrance of these somatic mutations within specific cancer patient populations will be extremely useful.

Understanding the biological relevance or significance of domain-specific mutations in the *mGluR1a* gene is essential to define their translational potentials in cancers. An important study by Esseltine and colleagues has elucidated the functional consequences of a number of somatic mutations in mGluR1a [@B84]. As shown in Table [2](#T2){ref-type="table"}, a large number of somatic mutations are clustered in the LBD of mGluR1a. A number of these LBD mutations, including A168V, R375G an d G396V, result in a reduction in the basal activity of the receptor [@B84]. Since it has been demonstrated that mGluR1a signaling pathways have a high basal level of activity as measured by G-protein activation [@B89], it is tempting to speculate that there is a selective advantage to reducing basal G-protein activity in cancer cells. However, since not all mutations follow this paradigm, the link between these LBD mutations, basal G-protein activity and mGluR1a signaling in cancer cells requires further investigation [@B84]. As discussed previously, Homer1 binding to mGluR1a can influence the active receptor at the level of subcellular localization and interaction with signaling components such as ERK1/2 [@B90]. The P1148L mutation, which is located in the Homer1 binding motif, results in not only mislocalization of the receptor, but also in reduced Homer1b binding - two consequences which have a major impact on receptor activity [@B84]. The P11148L and R696W mutations (located in the Homer1 binding motif and the TMD, respectively) were shown to influence mGluR1a-dependent phosphorylation of ERK1/2 without influencing the activation of lipid signaling [@B84]. These data indicate somatic mutations in mGluR1a can have second messenger-dependent effects on receptor signaling. Future studies may lead to not only more clues as to how mGluR1a functions in cancer cells, but also in possible diagnostic and prognostic tools.

Confirming at the transcript level that multiple GluR groups are involved in malignant disease, Stepulak, *et al.* conducted a study in which a panel of human tumor-derived cell lines were assayed for the expression of several iGluR and all eight mGluR genes [@B91]. Using semi-quantitative reverse transcription PCR (RT PCR), this work illustrated that multiple mGluRs are expressed in each of the 12 cell lines that were investigated. It should be noted that for mGluR1-8, the RT-PCR primers chosen were not able to differentiate between isoforms. The following human cell lines were interrogated for mGluR expression: rhabdomyosarcoma/medulloblastoma (TE671), neuroblastoma (SK-N-AS), thyroid carcinoma (FTC 238), lung carcinoma (SK-LU-1 and A549), astrocytoma (MOGGCCM), multiple myeloma (RPMI 8226), glioma (U87-MG and U343), colon adenocarcinoma (HT 29), T cell leukemia cells (Jurkat E6.1), breast carcinoma (T47D) and colon adenocarcinoma (LS180) [@B91]. These data are summarized in Table [3](#T3){ref-type="table"}.

In addition to the growing number of studies reporting GluR expression in malignant disease, Glu antagonists have been shown to have anti-proliferative and anti-migratory effects both *in vitro* and *in vivo* [@B92]. In a study designed to test the effect of Glu antagonists on migration and proliferation, Rzeski and colleagues exposed astrocytoma (MOGGCCM), rhabdomyosarcoma/medullobastoma (TE671), neuroblastoma (SK-NA-S) and thyroid carcinoma (FTC238) cells to the Glu antagonists dizocilpine and GYK152466 [@B92]. Interestingly, differential responses to the two drugs were seen in subsets of the cell lines. These effects were attributable to the ability of both drugs to block Ca^2+^ influx since growing the cells in a reduced-Ca^2+^ environment mitigated the effect [@B92]. Dizocilpine is widely known to cause a variety of unpleasant neural side effects including brain lesions and cognitive disruption which are likely due to both the drug\'s potent blockage of Ca^2+^ influx in NMDAR-expressing neurons and the pleiotropic role for Glu signaling in the nervous system [@B93]. Due to these side effects, the drug is not suitable for cancer therapy and is therefore not used in the clinic. However, these data are important in that they establish what is emerging as a general phenomenon: Glu antagonists and blockade of Glu release from cells has anti-tumor effects. Recalling that NMDARs are often coupled to Group I mGluRs, the mechanism for NMDAR involvement in tumor cell growth and migration may lie in mGluR signaling, after all. The mechanism of the effect of Glu antagonists on cancer cells is under-investigated.

Glutamate excitotoxicity and glioma
===================================

The role of glutamatergic signaling in the progression of glioma is well established (reviewed in [@B70], [@B94], [@B95]). Glioma represents the family of malignant tumors comprised of cells of glial origin and can contain ependymal cells, oligodendrocytes, astrocytes or a mixture of cell types. Making up 80% of all malignant brain diseases, gliomas can be either fast-growing or slow-growing, and that classification trends with treatability: slow-growing gliomas are more treatable and vice versa [@B96]. Importantly, glioma explants have been shown to continuously secrete Glu and therefore maintain a higher level of intra- and extracellular Glu than normal glial cells [@B97]. Tumors that secrete Glu are highly resistant to chemotherapy and standard apoptosis-inducing therapeutics - a phenomenon that may be mediated by the same mechanism whereby Glu functions as a survival factor at normal physiological doses in the developing nervous system [@B98]**.** However, too much Glu is known to be toxic, and although the malignant glioblastoma cells are themselves resist to excitotoxicity, neighboring neurons are not. Local apoptosis of neurons is commonly observed in glioma patients and is often a source of extensive brain tissue damage despite successful tumor resection [@B99]. In fact, it has been postulated that a selective infiltrative capacity for certain gliomas lies in their abilities to create more space for growth by killing neighboring cells [@B100]. Research has shown that excitotoxic levels of Glu arise from a shift in the balance between Glu transporter activity and secretion through the amino acid antiporter, cysteine-glutamine exchanger (X-c) (reviewed in [@B101] and below). The mechanisms by which normal cells secrete and remove Glu from the extracellular space are critically altered in transformed glial cells (reviewed in [@B70], [@B94]).

The role of EAAT in glioma-induced excitotoxicity has been well-studied. Normally, after stimulation of GluRs, Glu is emptied from the synaptic cleft or intracellular space by EAATs, of which there are multiple genes and splice variants in humans [@B33]. The role of EAATs in the growth and progression of glioma was studied in detail using the *in vitro* rat glioma cell line, C6 [@B33]. C6 cells normally express excitatory amino acid carrier 1 (EAAC1, an EAAT); however, clonal populations of the cell line have been shown not only to release Glu into the medium, but also to have selective loss of EAAC1 expression [@B33]. In animal models, Glu-releasing C6 clones showed a distinct growth advantage over those that did not secrete Glu. In addition, co-culture of Glu-secreting clones of C6 with neurons resulted in apoptosis of the neural populations [@B33]. It is counter-intuitive that gliomas such as astrocytoma release high levels of Glu into the extracellular space since a main function of normal astrocytes is to remove Glu post-signaling in the normal CNS. Immunohistochemical studies on human astrocytomas show a complete loss of the glutamate transporter-1 (GLT1) splice variant and aberrant localization of a second EAAT, glutamate/aspartate transporter (GLAST) [@B97]. It is likely not a coincidence that GLT1 and GLAST are the predominantly-expressed EAATs by astrocytes in the rat brain [@B102]. Together, the aforementioned studies indicate that impaired Glu transporter function and consequential constitutive Glu signaling is an important part of cellular transformation in glial cells. The observed reduction in EAAT activity in glioma is attributable to mGluR signaling (reviewed in [@B94], [@B103]). Expression of mGluR2, 3 and 5 but not 1 has been detected in normal glial cell types including astrocytes. Activation of mGluR3 or 5 with chemical agonists resulted in decreased EAAT (GLT1 and GLAST) expression in astrocytes in culture, demonstrating a direct link between mGluRs and EAAT expression. Importantly, glioblastoma cells display increased mGluR5 expression *in vivo* [@B104]. These data are suggestive of a direct role for mGluR in the fundamental change between normal astrocyte function and the transformed phenotype of reduced EAAT expression. Another important part in establishing an excitotoxic phenotype lies in the Glu secretion mechanism.

The method by which glioma cells release Glu into the extracellular space is mediated by the amino acid exchange antiporter, X-c [@B105]. This heterodimer catalyzes the exchange of extracellular cysteine for intracellular Glu at a 1:1 stoichiometric ratio. Many gliomas were found to have higher than normal levels of X-c - a significant reason for the accumulation of extracellular Glu [@B106]. As predicted given the results discussed thus far, silencing of X-c expression using small interfering RNA (siRNA) resulted in marked reduction in local apoptosis and brain swelling as well as reduced tumor growth rates [@B101], [@B107]. It is tempting, therefore, to assume that anti-X-c drugs would be potent treatments for glioma. Since the X-c antiporter has critical functions in the protection against oxidative stress outside of the nervous system, and since the loss of glutathione via X-c inhibition would therefore be cytotoxic, it is unlikely that anti-X-c therapies will be a viable option for glioma treatment [@B101], [@B107].

Downstream of the GluR family, phosphatase and tensin homolog (PTEN) and AKT signaling have been heavily implicated in glioma progression, resistance to chemotherapy and excitotoxicity. Loss of heterozygosity of PTEN has been shown for many cancers including glioma (as well as prostate, see [@B108] for a review). It is significant that the highly aggressive and most common form of glioma, glioblastoma multiforme, shows a higher penetrance of loss of PTEN function than the lower-grade astrocytomas [@B109]. The loss of PTEN-mediated inhibition of PI3K activity has important consequences for the cell: First, unchecked AKT activation leads to protection from excitotoxicity [@B103], [@B110], [@B111]. Second, since PTEN is also responsible for inhibiting Tumor necrosis factor-α (TNFα) signaling which activates nuclear factor κ enhancer of activated B cells (NFκB), elimination of TNFα inhibition results in overactive NFκB. This signaling situation is a well-known survival factor in many cancers [@B112]. It is clear from these data that glioma cells develop unique signaling adaptations that allow them to survive in an excitotoxic microenvironment. Treatments for glioma must involve shutting down these anti-apoptosis signals and removing toxic levels of Glu from the tumor microenvironment.

Glu antagonists have been extensively employed in the treatment of glioma. In recent years, there have been multiple significant failures of clinical trials utilizing other drugs families such as the receptor tyrosine kinase inhibitor family (reviewed in [@B113]). This may be partially due to the fact that inhibition of RTKs does not mitigate the release of Glu from glioma cells. Differential effects have been documented for iGluR and mGluR antagonists. First, the AMPAR/KR inhibitors, ZK 200775 and GYKI 52466, while having little effect on glioma growth *in vitro*, have pronounced anti-proliferative and anti-excitotoxic effects in rat hippocampal glioma models. Similar results were obtained for the NMDAR antagonists, norketamine [@B72] and MK801 (memantine) [@B33]. In fact, memantine has been employed in a Phase II clinical trial to determine its safety/efficacy in glioma patients; however results are not yet available (Clinicaltrials.gov \#NCT01260467). Similarly, the effectiveness of talampanel (an AMPAR antagonist) against glioma has been explored in the clinic. This study was completed with results that were not encouraging: no significant activity against glioma was observed (reviewed in [@B33], [@B94]).

Despite all of the preclinical work and clinical trials in progress or completed involving iGluR antagonists, studies targeting mGluR in glioma treatment are less commonly found. Perhaps the major discovery that gliomas release Glu and create excitotoxic local conditions within the brain will prompt new studies of this type. Indeed, a review by Roesler and colleagues in 2010 defines the family of mGluRs as "emerging targets" in glioma [@B114]. So far, no clinical trials are available using mGluR antagonists in glioma patients on Clinicaltrials.gov. Future studies in this field are clearly needed to determine the efficacy of mGluR antagonists and Glu release inhibitors such as riluzole against glioma.

mGluR expression causes cellular transformation in melanocytes
==============================================================

Although many reports of receptor expression in cell lines have been published, few population studies in human patient samples are available and few have established a mechanism for human mGluR in either carcinogenesis or disease progression. Certainly the first direct evidence for the oncogenic activity of the mGluRs was shown in melanocytes by Chen and colleagues [@B34], [@B115]. Overexpression of mGluR1 in non-cancerous melanocytes was sufficient to induce transformed phenotypes, indicating that mGluR1 functions as a proto-oncogene (reviewed in [@B33], [@B34]). Indeed, mGluR1 expression is detected in human melanoma samples and transformed melanoma cell lines, but not in benign nevi or normal melanocytes. In the pioneering study in the field, Pollock, *et. al* found that mGluR1 protein was expressed in 7 of 19 human melanoma biopsy samples and 12 of 18 human melanoma cell lines. As is the case in many studies, these data were obtained using western blot with an undescribed antibody and the resulting figure shows bands without any size marker or indication of the size of the protein [@B79]. In addition, due to the lack of mGluR isoform-specific antibodies, differential expression of mGluR1 isoforms could not be demonstrated. In agreement with these data, transgene insertion into an intron in the mouse *mGluR1* gene resulted in increased susceptibility to melanoma - furthering the model that mGluR1 may induce oncogenic transformation [@B79], [@B116]-[@B118]. Subsequent work demonstrated that the ectopic expression of murine mGluR1 in normal melanocytes *in vitro*was sufficient to induce rapid and aggressive tumor growth in nude mouse models. Angiogenesis and metastasis were readily apparent in this model, suggesting that the normal melanocytes were completely transformed by murine mGluR1 expression. Further, murine mGluR1 overexpression was found to be sufficient to cause malignant phenotypes in murine melanocytes both *in vitro* and *in vivo* [@B120]. Interestingly, constitutive expression of mGluR1 is required to maintain the transformed phenotype. Using a unique conditional expression system in transgenic mice, Ohtani*, et al.* showed that long-term expression of mGluR1 stimulated melanocytes growth and eventually led to melanoma, while silencing mGluR1 expression was sufficient to abrogate melanoma development [@B78]. This requirement for constitutive mGluR1 expression may indicate that mGluR1 is an ideal drug target [@B78].

Although the exact downstream signaling involved in the ability of mGluR1 to transform melanocytes is not yet known, some clues have been found using both genome-wide sequencing and candidate approach techniques. First, stimulation of Glu signaling in melanoma cell lines with mGluR agonists results in activation of MAPK; specifically ERK1/2 via active PKC [@B119]. Downstream activation of AKT2, but not AKT3, is found in mGluR1 overexpressed lines and this effect is enough to cause transformation in other cell lines [@B120], [@B121].

Whole-exome sequencing of melanoma and normal matched patient samples has revealed an accumulation of mutations in Glu signaling components including *GRIN2A* - an NMDAR subunit [@B70], [@B122]. Further studies have similarly implicated a number of other Glu signaling components: Mutations were found in the other NMDAR subunits *GRIN1* and *GRIN3*, as well as in *PLCβ4*, *mGluR3*, *PYK2* and receptor tyrosine-protein kinase erbB-4 (*ERBB4*) [@B70], [@B73]. PYK2 has been shown to interact directly with GRIN2A via PH-domain binding - further indicating a role for aberrant GluR signaling in cellular transformation [@B123]. Similarly, PLCβ4 is activated by mGluR signaling and produces the second messengers DAG and IP3.

Interestingly, mutations in mGluR3 were found to be selectively activating. Mutational analysis of mGluR3 *in vitro* demonstrated that recapitulation of the somatic mutations (found in patients) imparted increased activation of mitogen activated protein kinase kinase 1/2 (MEK 1/2). Phosphorylated MEK1/2 resulted in transformed phenotypes including loss of anchorage-dependency in growth regulation and increased migration [@B70]. Further, cells carrying the same mGluR3 mutations formed increased micrometastases *in vivo*[@B70]. Finally, ERBB4 is a well-known oncogene and its mutations are associated with increased risk not only for certain types of cancer, but also for schizophrenia [@B124]. As a downstream effector of mGluR1 signaling, these data represent an important link between GluRs and second messenger signaling mechanisms in melanoma. Follow-up studies have illustrated a link between constitutively active ERBB4 and increased invasion and migration in melanoma cells [@B125].

Drugs that block Glu release from the cell or otherwise disrupt Glu signaling have shown great promise in melanoma treatment in preclinical trials. It has been clearly demonstrated that transformed melanocytes release high levels of Glu into the medium. Similarly, glioma cells have also been shown to secrete Glu [@B33], [@B70]. Blockade of Glu release from melanocytes by riluzole results in decreased cell proliferation, suggesting an autocrine-like loop whereby mGluR1 expression is linked with increased extracellular Glu and proliferation. However, a direct causal relationship has not been established between mGluR activation and Glu release [@B126], [@B127]. Riluzole is able to suppress the growth of human melanoma xenografts *in vivo* by 50% compared to vehicle-treated controls [@B127]. Further, the Glu antagonists LY367385 and BAY36-7620 are also able to suppress proliferation and Glu release *in vitro*[@B127]. Taken together, these data lend further evidence to the hypothesis that riluzole, or other GluR antagonists, may have great potential in the treatment of melanoma. Indeed, a phase 0 clinical trial of riluzole in patients with advanced melanoma demonstrated a 34% success rate (n=12 patients, all expressing mGluR1) in decreasing tumor load [@B129]. Importantly, treated tumors showed decreased phospho-AKT (p-AKT) and/or p-ERK, indicating that the anti-tumor effect was due to inhibition of mGluR signaling [@B128]. Unfortunately, the follow-up phase II study with riluzole was not as successful, with no change in response evaluation criteria in solid tumors (RECIST) measurements. 42% of treated patients did not exhibit disease progression, however, implying that riluzole was at least able to suspend tumor growth in this population [@B129], [@B130]. Recent work has focused on combination therapies such as riluzole and the tyrosine kinase inhibitor, sorafenib [@B129]. Marketed by Bayer as Nexavar, sorafenib is a small molecule that targets the tyrosine kinases PDGF and VEGF as well as Raf kinases such as B- and C-Raf [@B131]. In preclinical studies using a combination of riluzole and sorafenib, significant inhibition of tumor growth was observed. These data were confirmed in cancer cell line investigated and were shown to be coincident with a reduction in p-ERK activity levels. A clinical trial to confirm these data in human melanoma patients is currently in progress (Clinicaltrials.gov \#NCT01303341).

In summary, a role for mGluR signaling in melanomagenesis has been clearly established. This heterogeneous malignancy is not simply cured by Glu blockade, however, given the less-than-impressive results of the phase II trial that was conducted on riluzole in late-stage mGluR1-expressing melanoma patients. These results may be explainable by the mechanism of action of riluzole. It is likely that blocking the release of Glu from the cell is not enough to exert an anti-tumor effect in human patients. Combination therapy involving riluzole and either tyrosine kinase inhibitors like sorafenib or radiation treatment may provide some relief for patients suffering from this aggressive tumor. The next few years will be critical for this field: If riluzole is not the key to block Glu signaling in transformed melanocytes, then new drugs as Glu-release inhibitor or competitive or non-competitive Glu receptor inhibitor will need to be developed.

Preliminary studies suggest that riluzole is effective against breast carcinoma
===============================================================================

Breast cancer, a "steroid hormone dependent" carcinoma, represents a group of malignancies with characteristic steroid receptor expression and steroid hormone responsiveness. Despite the decades of research and successes in treating estrogen receptor (ER)-positive, progesterone receptor (PR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancers, patients that are negative for these markers (triple negative breast cancers; TNBCs) have been forced to rely on broad-spectrum cytotoxic agents [@B132]. Research that identifies hormone-independent markers and therapeutic targets for these specific breast cancers are needed.

Following the recent explosion of interest in Glu signaling in melanomagenesis and treatment, Speyer and colleagues undertook a pilot study to determine the role of mGluR signaling in breast cancer [@B133]. First, mGluR1 expression was assayed in a number of TNBC breast cancer cell lines. Including normal breast epithelial cells, all of the cell lines examined were found to express mGluR1 protein [@B133]. Furthermore, Glu signaling was active in these cells since phospho-AKT2 (p-AKT) was stimulated by the AMPA/mGluR1 Group 1 agonist, quisqualic acid and inhibited by the non-competitive mGluR1 antagonist, BAY36-7620 [@B133]. Similar to the findings discussed above for melanoma cells in culture, TNBC cell growth is inhibited by mGluR1 antagonists and shRNA knockdown of mGluR1 resulted in a statistically significant reduction in proliferation [@B133]. As was the case in other studies of this nature and for the same reasons described before, no differentiation among isoforms of mGluR1 was made and it is still unknown whether one isoform is more important than another in the regulation of cancer cell proliferation. In fact, knockdown was assayed at the level of mRNA expression using primers that are homologous to both the mGluR1a and mGluR1b mRNAs, indicating that both isoforms may have been knocked down using this shRNA (determination made by BLASTn search). Nevertheless, these results are significant in that they establish that for TNBCs, mGluR1 may play a similar role in tumor growth and possibly even transformation as has been shown for melanomagenesis. Interestingly, another group has reported that breast cancer cells secrete Glu into the medium, indicating that glioma, melanoma and breast cancer may have some intriguing similarities [@B134], [@B135].

In a TNBC xenograft model, doses of riluzole that were found to be effective in treating ALS patients showed up to 80% decrease in tumor volume [@B133], further indicating that mGluR and Glu signaling are emerging therapeutic targets in breast cancer treatment. We postulate that multiple studies are underway at the time of the writing of this review and that the coming years in the field of Glu signaling in TNBC research will be very interesting.

Glutamate and glutamate receptors in prostate cancer cells and tissues
======================================================================

The role of Glu signaling in prostate carcinogenesis and progression has not been investigated until very recently. In 2009, one study was published which suggested that subsets of mGluR genes are expressed in the PCa cell lines PC-3 and LNCaP [@B71]. It is interesting to note that different subsets of NMDARs and mGluRs were detected in the two cell lines - but the functional significance of these data remains unknown [@B71].

We recently reported that serum Glu levels correlate with primary PCa aggressiveness and that Glu antagonists decrease PCa cell proliferation [@B31]. Most importantly, the clinical significance of Glu signaling in PCa was determined by measuring serum-Glu levels in normal adult males and patients with primary untreated organ-confined or metastatic castrate-resistant tumors [@B31]. Using Gleason score (GS) as a pathologic grading pattern (reflecting PCa aggressiveness or lethality) and other clinical parameters (PSA and clinical stage) to divide primary PCa into the clinically low, mid, or high aggressiveness subgroups, it was found that higher serum Glu levels correlated with higher GS (\>8) and more aggressive disease [@B31]. Further, racial disparity was found: African American (AA) PCa patients had higher serum Glu levels than Caucasian PCa patients. In AAs, serum-Glu levels in metastatic castrate-resistant PCa (mCRPCa) were also found to be higher than in the primary PCa (early stage and less aggressive) or normal research subjects [@B31]. Although the source of increased circulating Glu is unknown at this time, it is tempting to speculate that PCa cells release Glu into the serum - as has been shown for breast cancer cells in culture and glioma in human or rodent cell systems. Furthermore, we have also detected extracellular Glu release in Glu-depleted conditioned media collected from different PCa cell lines (Koochekpour *et al*, unpublished data). In addition, our descriptive pilot study demonstrated mGluR1a (also known as GRM1a) overexpression in primary and metastatic PCa tissues [@B31], [@B32].

The clinical significance of these studies lies in the fact that Glu has the potential to serve as a metabolic serum biomarker for primary PCa in Caucasians and/or for primary and metastatic PCa in African Americans. In addition, mGluR1a may also serve as a molecular target for therapeutic interventions in both African Americans and Caucasians. In fact, microarray studies have previously demonstrated that targeting the AKT/mTOR pathway with anti-mTOR or anti-MAPK/ERK drugs resulted in decreased growth of PCa cell lines *in vitro*[@B136]. Taken together, these data prompt a model in which glutamatergic signaling presents itself as a critical druggable target for PCa.

In PCa cell lines, mGluR1 is detected and Glu signaling plays a role in growth regulation [@B31]. As we previously published, not only is mGluR1 expression is detected at high levels in high-grade human PCa tumors, but also, in PCa cell lines, multiple bands of varying size are detected on western blot using a commercial anti-mGluR1 antibody (1:1000; Proteintech Group, Chicago, IL. Catalog \#19955) [@B31]. Interestingly, the predominant band (i.e. \~75 KDa) that is detected with this antibody (which was raised against an N-terminal peptide) is significantly smaller than the predicted monomeric molecular weight of \~125 KDa for mGluR1a, which may indicate that the protein is processed in some way in PCa cells. This phenomenon was global: All 7 PCa cell lines tested displayed this smaller band, regardless of their androgen responsiveness or the clinical aggressiveness of their tumors of origin [@B31]. Glu signaling in these lines is functional, since inhibition with the antagonists BAY36-7620 or riluzole and deprivation of Glu were both able to significantly decrease PCa cells growth. In fact, riluzole induced apoptosis in a time- and dose-dependent manner in PCa cells [@B31]. This effect was mediated by activation of caspases, since levels of cleaved caspase-3, -7 and -9 and -PARP were increased with increased doses of riluzole. Finally, both antagonists were also able to suppress two of the most important malignancy-associated phenotypes: migration and invasion. This study prompts the model that high serum Glu levels create a favorable growth environment or microenvironment for PCa. It will be critical to determine whether this is the case for other cancers (e.g. breast, melanoma and glioma) where Glu antagonists have shown anti-proliferative effects. Large scale clinical studies will certainly be necessary to define clinical and histopathological significance of Glu (ligand) and mGLuR1 (receptor) expression and signaling in PCa. It is noteworthy a non-invasive serum Glu test either alone or in combination with other PCa biomarkers \[prostate cancer 3 (PCA3) for example; see [@B108] for review\] for PCa diagnosis could potentially aid in early-stage diagnosis and treatment planning. Finally. Glu antagonists may serve as novel therapeutic agents for PCa [@B32].

Concluding remarks
==================

Research into the role of Glu signaling in cancer development and progression is still in its infancy; however, important progress has been made in recent years. The discovery that rodent mGluR overexpression is sufficient for cellular transformation in cultured melanocytes has had a tremendous impact on the field. Further, the ability of glioma, and possibly advanced TNBCs, to secrete Glu into the tumor microenvironment has prompted the question of whether this feature is common to other types of cancers [@B94], [@B134], [@B135]. It is tempting to speculate that both glioma and melanoma originate from cells of the ectodermal germ layer or simply share a common neuroendocrine origin given the similarities between the malignancies. Interestingly, neuroendocrine cells also exist in both benign and malignant prostate tissues and the neuroendocrine differentiation pathway is believed to be one of the most important mechanisms for the development of castrate-resistant PCa. In Figure [3](#F3){ref-type="fig"}, we present the similarities and differences among the cancers that have been discussed in this review. It is clear that more research is needed to define the clinical and histopathological significance of Glu-mGlUR expression and signaling in glioma, melanoma, breast cancer, and PCa. Given these preliminary studies, it will be extremely interesting to follow the field of glutamatergic signaling in cancer in future years.

This work was supported by Roswell Park Cancer Institute and National Cancer Institute (NCI) grant \#P30 CA016056. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or National Cancer Institute.

![iGluR activation. This figure illustrates the activation and opening of iGluR ion channels. In Panel A, the closed channel does not allow ion influx. Upon Glu binding (Panel B), conformational change in iGluR subunits allows Ca^2+^ influx to occur by diffusion through the open channel.](ijbsv09p0728g01){#F1}

![mGluR activation. This figure depicts the mGluR1a receptor before (Panel A) and after (Panel B) Glu binding. Relevant domains are noted, such as: amino terminal domain (ATD), cysteine-rich domain (CRD), transmembrane domain (TMD), cytoplasmic tail domain (CTD). Binding of Glu activates G-protein signaling and downstream second messenger pathways including PKC, PLC and Ca^2+^ signaling.](ijbsv09p0728g02){#F2}

![GluR involvement in different cancer types. This Venn diagram illustrates the similarities and differences among the four cancer types with respect to the involvement of glutamatergic signaling. Glioma, breast cancer, prostate cancer and melanoma are represented by the circles. Overlapping areas indicate the expressional and functional similarities for GluR genes among different cancer types investigated. For example, mGluR proteins have been detected in all four cancer types, therefore this phrase is in an area where all four circles overlap.](ijbsv09p0728g03){#F3}

###### 

Ionotropic and metabotropic glutamate receptor families.

  Glutamate receptor family   Subgroup   \# of genes                                                  Second messenger signaling system
  --------------------------- ---------- ------------------------------------------------------------ -------------------------------------------------------------------
  **iGluR**                   NMDAR      7                                                            Ca^2+^, K+ influx
  AMPAR                       4          Ca^2+^, K+ influx                                            
  Kainate                     5          Ca^2+^, K+ influx                                            
  **mGluR**                   Group I    2                                                            Ca^2+^, coupling to K+ channels, PLC/IP3/DAG, PI3K/AKT/mTOR, MAPK
  Group II                    2          Inhibition of adenylyl cyclase; shutdown of cAMP signaling   
  Group III                   4          Inhibition of adenylyl cyclase; shutdown of cAMP signaling   

###### 

Somatic mutations identified in the *mGluR1a* gene in cancer patients.

  Domain                 Mutation   Type       Reference
  ---------------------- ---------- ---------- -----------
  LBD ( n = 19 )         S33L       Missense   85
  D44E                   Missense   81         
  R71K                   Missense   85         
  R78H                   Missense   138        
  D87H                   Missense   138        
  A91T                   Missense   TCGA\*     
  K153N                  Missense   TCGA       
  A168V                  Missense   81         
  A184T                  Missense   86         
  W224C                  Missense   138        
  A229S                  Missense   138        
  R275H                  Missense   TCGA       
  R297 - STOP            Nonsense   84         
  R375G                  Missense   81         
  E386 - STOP            Nonsense   81         
  G396V                  Missense   81         
  I414V                  Missense   TCGA       
  P444L                  Missense   88         
  C547F                  Missense   85         
  TMD loops ( n = 10 )   D619A      Missense   87
  S626C                  Missense   137        
  T655N                  Missense   TCGA       
  R661H                  Missense   TCGA       
  R684C                  Missense   82         
  G688V                  Missense   81         
  R696W                  Missense   83         
  Q706 - STOP            Nonsense   85         
  N782I                  Missense   TCGA       
  S783I                  Missense   87         
  CTD ( n = 4 )          R967H      Missense   137
  E1006K                 Missense   85         
  D1096N                 Missense   138        
  P1148L                 Missense   84         

\*TCGA: The cancer genome atlas. <http://cancergenome.nih.gov>.

###### 

Glutamate receptor expression and effective antagonists in different cancer cell lines.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer type                Cell line                                             GluR genes detected                           Glu antagonists with growth inhibitory effect   Refs
  -------------------------- ----------------------------------------------------- --------------------------------------------- ----------------------------------------------- -------------------------------
  **Glioma**                 U87-MG, U343, C6                                      mGluR1-8, NR2-3, GluR2-7, KA1-2               Memantine, MK801                                [@B33], [@B91]

  **Neuroblastoma**          SK-N-AS                                               mGluR2-8, NR1-3, GluR2-4, 6-7, KA1-2          Dizocilpine, GYKI 52466                         [@B91]

  **Rhabdomyosarcoma**\      TE671                                                 mGluR2-4, 6-8, NR1-3, KA1-2, GluR2, 4, 6, 7   Dizocilpine, GYKI 52466                         [@B91]
  **&**\                                                                                                                                                                         
  **Medulloblastoma**                                                                                                                                                            

  **Astrocytoma**            MOGGCCM                                               mGluR1-8, NR1-3, KA1-2, GluR1-4; GluR6-7      Dizocilpine, GYKI 52466                         [@B91]

  **Lung carcinoma**         SK-LU-1                                               mGluR1-2, 4-8, NR1-3, KA1-2, GluR1-2, 4, 6    N.D.                                            [@B91]

  **Colon adenocarcinoma**   HT29, LS180                                           mGluR1-8, NR1-3, KA1-2, GluR1-2, 4, 6-7       Dizocilpine, GYKI 52466                         [@B91]

  **T-cell leukemia**        Jurkat E6.1                                           mGluR1-7, NR2-3, KA1-2, GluR2-4, 6-7          N.D.                                            [@B91]

  **Multiple myeloma**       RPMI 8226                                             mGluR2-7, NR1-2, KA1-2, GluR4, 6              N.D.                                            [@B91]

  **Breast carcinoma**       T47D                                                  mGluR1-7, NR1-3, KA1-2, GluR2, 4-7            Dizocilpine, BAY36-7620, riluzole, GYKI 52466   [@B91], [@B133]

  **Thyroid carcinoma**      FTC 238                                               mGluR2, 4, 7, NR1-3, KA1-2, GluR2-4, 6-7      Dizocilpine, GYKI 52466                         [@B91]

  **Prostate carcinoma**     PC-3, LNCaP, DU145, VCaP, 22RV1, E006AA, MDA-PCa2B,   mGluR1a, mGluR1-8, NR1-3                      Riluzole, BAY36-7620                            [@B32], [@B61],[@B71], [@B91]

  **Melanoma**               C8161, UACC903, HT144, SKMEL2                         mGluR1                                        Riluzole, BAY36-7620                            [@B130]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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